Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
TARGET investigator’s study of nearly 1,000 pediatric acute myeloid leukemia (AML) cases reveals marked differences between the genomic landscapes of pediatric and adult AML and offers directions for future work.
TARGET’s AML researchers demonstrate that recurrent structural alterations and age-specific mutational profiles can be used stratify pediatric subjects in terms of both overall and progression-free survival, and highlight the need for age-tailored targeted therapies for pediatric AML.
CTD2 researchers at DFCI developed CERES, a computational approach to improve the specificity of genome-wide loss-of-function CRISPR-Cas9 screens by decreasing the discovery of false-positives.
CTD2 scientists at Emory University developed the OncoPPi Portal, an interactive web resource to explore cancer-relevant protein-protein interactions that were experimentally identified in cancer cell lines.
CTD2 scientists used Project Achilles (RNAi screening) data in a community DREAM challenge (that assessed computational models focused on biomedical research problems) to predict the gene essentiality. This study provides insights into factors influencing the ability to predict gene essentiality.
TARGET investigators examined whether circulating miRNAs can be used as prognostic biomarkers in osteosarcoma patients. miR-21, miR-221, and miR-106a were found to be expressed significantly higher in cancer samples and were correlated with outcome.
CTD2 scientists at UCSF (1), Broad Institute, and TGen have identified that drug-tolerant persister cancer cells from multiple tumor types that survive chemotherapy were found to be vulnerable to chemical inhibition or genetic loss of function of GPX4.
UCSF (1) researchers identified genetic alterations that assist primary drivers, as co-drivers, that promote tumor growth and drug resistance in advanced-stage EGFR-mutant lung cancers.
CTD2 scientists at UT MD Anderson Cancer Center developed a user-friendly bioinformatic resource, The Cancer Proteome Atlas (TCPA). This resource contains the expression levels of key cancer proteins (characterized by reverse-phase protein arrays) from patient tumors and cancer cell lines.
TARGET’s AML researchers identified abundant expression of miR-106a, a marker for treatment resistance, in relapsed and refractory pediatric AML through a comprehensive miRNA profile to identify potential biomarkers as predictors for improved outcomes.